Palopegteriparatide
Also known as: Yorvipath, TransCon PTH
A long-acting PTH(1-34) prodrug FDA-approved in 2024 as Yorvipath for hypoparathyroidism in adults. Prescription medication.
Last updated
Mechanism of Action
Palopegteriparatide is teriparatide, PTH(1-34), transiently linked to a methoxy-polyethylene glycol carrier through Ascendis Pharma's TransCon linker. After once-daily subcutaneous injection the linker cleaves slowly, releasing active PTH(1-34) to give steady PTH levels across 24 hours. Continuous PTH1R activation in kidney and bone restores calcium reabsorption, vitamin D activation and phosphate excretion, replacing the missing hormone.
- Half-life
- ~60 hours (released PTH)
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Normal serum calcium without conventional active vitamin D or high-dose calcium in most PaTHway patients
- Lowers urinary calcium excretion
- Improved kidney function (eGFR) in phase 3 follow-up
- Improved hypoparathyroidism-related quality-of-life scores
Potential Side Effects
- Injection-site reactions
- Headache, flushing, dizziness and orthostatic hypotension
- Hypercalcemia and hypocalcemia, especially during titration or after stopping
- Potential osteosarcoma risk based on animal data (warning)
Common Dosing
Labeled dosing starts at 18 mcg injected subcutaneously once daily and is adjusted in small steps based on serum calcium, while conventional calcium and active vitamin D are tapered. It comes in prefilled dose-adjustable pens. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Increased osteosarcoma risk (Paget's disease, open epiphyses, prior skeletal radiation): weigh carefully
- Acute post-surgical hypoparathyroidism (not evaluated)
- Digoxin use requires closer calcium monitoring
No documented stacking partners for Palopegteriparatide yet.
- View
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
2022
- View
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
2023
- View
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
2025